| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Lanostenol targets cholesterol biosynthesis by promoting ubiquitination and degradation of HMG-CoA reductase. It is also a substrate of CYP51, the enzyme responsible for sterol 14α-demethylation in cholesterol biosynthesis. By inhibiting HMG-CoA reductase degradation, it reduces cholesterol synthesis.
|
|---|---|
| ln Vitro |
In vitro, lanostenol is a substrate of CYP51 and an inhibitor of cholesterol synthesis. It promotes ubiquitination and degradation of HMG-CoA reductase. The compound is used in cholesterol biosynthesis research and sterol metabolism studies. It supports experimental work on pathway intermediates and sterol regulation.
|
| ln Vivo |
In vivo, lanostenol is a naturally occurring metabolite in humans and mice. It inhibits cholesterol biosynthesis through its effects on HMG-CoA reductase. The compound is a 3β-sterol and a tetracyclic triterpenoid, functioning similarly to lanosterol.
|
| Enzyme Assay |
In vitro enzyme assays for lanostenol measure its activity as a substrate of CYP51. The compound's ability to promote ubiquitination and degradation of HMG-CoA reductase is assessed in cell-free systems or cell-based assays. Cholesterol synthesis inhibition is measured by tracking incorporation of labeled precursors into cholesterol.
|
| Cell Assay |
In vitro cell-based assays for lanostenol assess its effects on cholesterol synthesis and HMG-CoA reductase stability. Cells are treated with serial dilutions of the compound, and cholesterol synthesis is measured by incorporation of radiolabeled acetate or mevalonate. HMG-CoA reductase protein levels are assessed by Western blotting.
|
| Animal Protocol |
In vivo animal models for lanostenol include studies of cholesterol metabolism and sterol regulation. The compound is a naturally occurring metabolite in humans and mice. It is used in investigations involving CYP51-related enzymatic activity. Rodent models are used to study its effects on cholesterol biosynthesis and lipid metabolism.
|
| ADME/Pharmacokinetics |
Lanostenol has a molecular formula of C₃₀H₅₂O and a molecular weight of 428.73 g/mol. It is also known as 24,25-Dihydrolanosterol, Dihydrolanosterin, and DHL. It is a 3β-sterol and a tetracyclic triterpenoid. The compound is a human and mouse metabolite. It is stored under appropriate conditions for research use.
|
| Toxicity/Toxicokinetics |
Lanostenol is a naturally occurring metabolite and is not known to have significant toxicity. It is a substrate of CYP51 and an inhibitor of cholesterol synthesis. The compound is for research use only and is not approved for clinical use. Appropriate safety precautions should be taken during handling.
|
| References | |
| Additional Infomation |
24,25-Dihydrolanosterol is a 3β-sterol formed by the reduction of lanosterol via the C-24-C-25 double bond. It is a metabolite in both humans and mice. It is a 3β-sterol and a tetracyclic triterpenoid. Its function is related to that of lanosterol. 24,25-Dihydrolanosterol has been reported to exist in Mortierella alpina, Capsicum annuum, and other organisms with relevant data. 24,25-Dihydrolanosterol is a metabolite found or produced in Saccharomyces cerevisiae.
Lanostenol (24,25-Dihydrolanosterol, Dihydrolanosterin, DHL) is a 3β-sterol formed by reduction of lanosterol. It is a substrate of CYP51 and inhibits cholesterol biosynthesis by promoting ubiquitination and degradation of HMG-CoA reductase. It is a human and mouse metabolite. Lanostenol is used in cholesterol biosynthesis research and sterol metabolism studies. |
| Molecular Formula |
C30H52O
|
|---|---|
| Molecular Weight |
428.74
|
| Exact Mass |
428.402
|
| CAS # |
79-62-9
|
| Related CAS # |
Dihydrolanosterol-d7;2260669-12-1
|
| PubChem CID |
440560
|
| Appearance |
White to off-white solid powder
|
| LogP |
8.559
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
31
|
| Complexity |
716
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C[C@H](CCCC(C)C)[C@H]1CC[C@@]2([C@@]1(CCC3=C2CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)C)C
|
| InChi Key |
MBZYKEVPFYHDOH-BQNIITSRSA-N
|
| InChi Code |
InChI=1S/C30H52O/c1-20(2)10-9-11-21(3)22-14-18-30(8)24-12-13-25-27(4,5)26(31)16-17-28(25,6)23(24)15-19-29(22,30)7/h20-22,25-26,31H,9-19H2,1-8H3/t21-,22-,25+,26+,28-,29-,30+/m1/s1
|
| Chemical Name |
(3S,5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol
|
| Synonyms |
Dihydrolanosterol; Dihydrolanosterin; Lanostenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol : ~12.5 mg/mL (~29.16 mM)
DMSO :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.92 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (2.92 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear EtOH stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3324 mL | 11.6621 mL | 23.3242 mL | |
| 5 mM | 0.4665 mL | 2.3324 mL | 4.6648 mL | |
| 10 mM | 0.2332 mL | 1.1662 mL | 2.3324 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
